Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 1) Healthy males and females 15 months of age with no active liver disease and a negative history of hepatitis A who have been vaccinated against Haemophilus influenzae type b (Hib), diphtheria, tetanus, and pertussis diseases~* Stage 2) Healthy males and females 12 to 17 months of age with no active liver disease and a negative history of hepatitis A~Exclusion Criteria:~* Stage 1) Males and females previously vaccinated with hepatitis A vaccine, any immune deficiency, a history of allergy to any of the vaccine components, a history of seizure disorder or a neurologic disorder that would contraindicate pertussis vaccine, or a bleeding disorder~* Stage 2) Males and females previously vaccinated with hepatitis A vaccine, any immune deficiency, a history of allergy to any of the vaccine components, or a history of bleeding disorder

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 17 Months
- Healthy Volunteers: t

Study Arms:
- VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1) (Type: EXPERIMENTAL): Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered.
- PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1) (Type: EXPERIMENTAL): Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered.
- VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1) (Type: EXPERIMENTAL): Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered.
- PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1) (Type: EXPERIMENTAL): Day 1: PedvaxHIB™ was administered.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered.
- VAQTA™/VAQTA™ (Stage 2) (Type: EXPERIMENTAL): Day 1: The first dose of VAQTA™ was administered.~Week 24: The second dose of VAQTA™ was administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).